Published in Neuroimage Clin on February 07, 2015
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain (2016) 0.77
Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Mov Disord (2016) 0.75
Brain structural changes in women and men during midlife. Neurosci Lett (2016) 0.75
Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. PLoS One (2017) 0.75
Whole brain analysis of postmortem density changes of grey and white matter on computed tomography by statistical parametric mapping. Eur Radiol (2016) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
A global optimisation method for robust affine registration of brain images. Med Image Anal (2001) 27.87
Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp (2002) 25.56
Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging (2001) 25.22
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology (1994) 21.65
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord (2003) 6.94
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet (2001) 4.28
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging (1998) 2.75
Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr (2001) 2.67
One-year brain atrophy evident in healthy aging. J Neurosci (2009) 2.61
Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90
Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology (2009) 1.88
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology (2000) 1.85
Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology (2005) 1.73
CAMCOG--a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. Br J Clin Psychol (1995) 1.62
The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry (2000) 1.61
Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology (2011) 1.60
Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology (2006) 1.57
Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology (2008) 1.56
Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects. Neuroimage (2004) 1.53
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage (2002) 1.44
Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage (2007) 1.37
Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology (2001) 1.32
Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol (2002) 1.09
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol (2007) 1.05
Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord (2005) 0.97
Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology (2012) 0.97
Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study. Int Psychogeriatr (2011) 0.96
Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. Arch Neurol (2000) 0.93
Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res Ther (2014) 0.93
Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. Psychiatry Res (2011) 0.90
Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. Brain Pathol (2014) 0.97
Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. Neurobiol Aging (2014) 0.81
18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain (2017) 0.81
Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. J Cereb Blood Flow Metab (2016) 0.80
The impact and measurement of social dysfunction in late-life depression: an evaluation of current methods with a focus on wearable technology. Int J Geriatr Psychiatry (2016) 0.76
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). Int J Geriatr Psychiatry (2016) 0.76
Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol Assess (2017) 0.76
Management of late-life depression: a major leap forward. Lancet (2015) 0.75
The segregated connectome of late-life depression: a combined cortical thickness and structural covariance analysis. Neurobiol Aging (2016) 0.75
A spatial covariance (123)I-5IA-85380 SPECT study of α4β2 nicotinic receptors in Alzheimer's disease. Neurobiol Aging (2016) 0.75
Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. J Neurol Neurosurg Psychiatry (2017) 0.75
Epigenetic regulation in the pathophysiology of Lewy body dementia. Prog Neurobiol (2020) 0.75
Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile. Psychol Med (2020) 0.75
Gray matter changes related to microglial activation in Alzheimer's disease. Neurobiol Aging (2020) 0.75
The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson's disease dementia. Eur J Neurol (2022) 0.75
[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry (2017) 0.75
The influence of hippocampal atrophy on the cognitive phenotype of dementia with Lewy bodies. Int J Geriatr Psychiatry (2017) 0.75